Elos appoints Johannes Lind-Widestam as new President and CEO as of 1 February 2015

Report this content

President and CEO Göran Brorsson has decided to step down as of 31 January 2015

Following more than 14 years as President and CEO of Elos (former Westergyllen), President and CEO Göran Brorsson has decided to step down as of 31 January 2015.

Göran Brorsson will be succeeded by Johannes Lind-Widestam, who will take office on 1 February 2015. Johannes Lind-Widestam will join Elos from Assa Oem AB, where he is president. Previously, Lind-Widestam was Purchasing Director at Nobel Biocare and responsible for Swedish operations at Kitron.

Stig-Arne Blom, Chairman of the Elos Board, comments as follows: “We are delighted to have been able to have tied Johannes Lind-Widestam to us as our new CEO. Johannes has the personality and the professional credentials that make him ideal to take over the leadership of Elos. His task will be to further develop our operations on a global basis.

“At the same time, I would like to thank Göran Brorsson for his efforts during his time as CEO. Under Göran’s leadership, the Group has been transformed from an industrial conglomerate to Elos Medtech, a niche operation in the medical technology area, with a strong market position and healthy profitability.”

Johannes Lind-Widestam comments as follows: “Since my time at Nobel Biocare, I have known Elos as a proactive and quality-oriented company. It feels extremely inspiring having the opportunity to take over as CEO of the Group.” 

Göran Brorsson says: “Implementing a comprehensive transformation of the Elos (former Westergyllen) Group has been an exciting task. Today, Elos is established as Elos Medtech, with a stable market position that constitutes an excellent platform for continued growth. With the strong financial base that the Group has today, it feels good handing over to Johannes who, with his excellent credentials, has solid prerequisites for further growing the business.”

Elos Medtech is today one of Europe’s leading partners in the development and production of medical technology products and components, such as dental and orthopaedic implants and instruments. Operations are conducted at facilities in Sweden, Denmark and China. The customer base comprises market-leading, internationally active medical-technology companies.

Lidköping, 24 October 2014

Elos AB (publ)

For further information, please contact: Stig-Arne Blom, Chairman of the Board, phone 46 705 25 16 15, e-mail stigarne@blom.pp.se 

For additional information Elos Group, visit www.elos.se  

The information of this press release is of the kind that Elos AB (publ) has to make public according to the Securities Market Act and/or the Financial Instruments Trading Act. The information was made public on 24 October, 2014 at 08:05 a.m. (CET).

Tags:

Subscribe

Documents & Links